<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2801">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01479764</url>
  </required_header>
  <id_info>
    <org_study_id>P07981</org_study_id>
    <secondary_id>MK-8616-064</secondary_id>
    <nct_id>NCT01479764</nct_id>
  </id_info>
  <brief_title>Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)</brief_title>
  <official_title>Effect of Sugammadex Compared With Usual Care for Reversal of Neuromuscular Blockade Induced by Rocuronium on Incidence of Residual Blockade at PACU Entry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the incidence of residual neuromuscular blockade in participants who
      undergo reversal of neuromuscular blockade with sugammadex compared to those who undergo
      reversal of neuromuscular blockade with usual care (neostigmine/glycopyrrolate).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of Residual Neuromuscular Blockade (NMB) as Defined by a Train-of-Four (TOF) Ratio &lt;0.9 at Post Anesthesia Care Unit (PACU) Entry</measure>
    <time_frame>At PACU entry on Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Neuromuscular functioning was monitored by applying four TOF electrical stimulations to the ulnar nerve and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (height) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB, with a higher ratio indicating greater recovery from NMB. A T4/T1 Ratio of &lt;0.9 is indicative of residual NMB.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time From Start of Study Drug Administration to Operating Room Discharge-ready</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time of operating room discharge readiness was determined by the surgical team based on clinical evaluations.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Surgical Procedures, Elective</condition>
  <arm_group>
    <arm_group_label>Sugammadex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive sugammadex, 2 or 4 mg/kg, depending on level of neuromuscular recovery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine/glycopyrrolate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive neostigmine/glycopyrrolate per usual practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>sugammadex, intravenous (IV) bolus, 2 or 4 mg/kg depending on level of neuromuscular recovery</description>
    <arm_group_label>Sugammadex</arm_group_label>
    <other_name>SCH 900616, MK-8616</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>neostigmine, per usual practice</description>
    <arm_group_label>Neostigmine/glycopyrrolate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate</intervention_name>
    <description>glycopyrrolate per usual practice</description>
    <arm_group_label>Neostigmine/glycopyrrolate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists (ASA) Class 1 or 2 or 3

          -  Scheduled to undergo an elective abdominal surgical procedure under general
             anesthesia; and:

               -  expected to undergo neuromuscular relaxation with rocuronium for

        endotracheal intubation; and

          -  expected to require at least one maintenance dose of rocuronium; and

          -  expected to require active reversal of neuromuscular blockade; and

          -  expected to require clinical or subjective neuromuscular monitoring only; and

          -  expected to recover in the PACU

               -  Arm that is accessible for measuring the TOF ratio in the PACU

               -  Sexually active female patient of child-bearing potential must agree to use a

        medically accepted method of contraception through seven days after receiving

        protocol-specified medication.

        Exclusion Criteria:

          -  Anatomical malformations that may lead to difficult intubation

          -  Neuromuscular disorder(s) that may affect neuromuscular blockade and/or trial
             assessments

          -  Dialysis-dependent or has or is suspected of having severe renal insufficiency

          -  Significant hepatic dysfunction

          -  Family history of malignant hyperthermia

          -  Cardiac pacemaker

          -  Allergy to study treatments or its/their excipients, to opioids / opiates,
             sugammadex, muscle relaxants or their excipients, or other medication(s) used during
             general anesthesia

          -  Toremifene before or within 24 hours of study drug administration

          -  Scheduled for an overnight stay (or &gt;12 hours) in PACU

          -  Expected transfer to an Intensive Care Unit after surgery

          -  Pregnant, intention to become pregnant between randomization and the Day 30 pregnancy
             follow-up visit

          -  Breast-feeding.

          -  Investigational drug(s) within 30 days of randomization on this study

          -  Participation in any other clinical trial within 30 days, inclusive, of signing the
             informed consent form of the current trial

          -  Participant or family member is among the personnel of the investigational or Sponsor
             staff directly involved with this trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Brueckmann B, Sasaki N, Grobara P, Li MK, Woo T, de Bie J, Maktabi M, Lee J, Kwo J, Pino R, Sabouri AS, McGovern F, Staehr-Rye AK, Eikermann M. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study. Br J Anaesth. 2015 Nov;115(5):743-51. doi: 10.1093/bja/aev104. Epub 2015 May 2.</citation>
    <PMID>25935840</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 5, 2015</lastchanged_date>
  <firstreceived_date>November 22, 2011</firstreceived_date>
  <firstreceived_results_date>August 26, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sugammadex</title>
          <description>Participants receive a single intravenous (IV) bolus dose of sugammadex, 2 or 4 mg/kg, depending on level of neuromuscular recovery</description>
        </group>
        <group group_id="P2">
          <title>Neostigmine/Glycopyrrolate</title>
          <description>Participants receive a single IV bolus dose of neostigmine/glycopyrrolate (neostigmine total dose not to exceed 5 mg) per usual practice</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74">2 randomized participants did not receive study drug</participants>
                <participants group_id="P2" count="77">1 randomized participant did not receive study drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treated</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sugammadex</title>
          <description>Participants receive a single intravenous (IV) bolus dose of sugammadex, 2 or 4 mg/kg, depending on level of neuromuscular recovery</description>
        </group>
        <group group_id="B2">
          <title>Neostigmine/Glycopyrrolate</title>
          <description>Participants receive a single IV bolus dose of neostigmine/glycopyrrolate (neostigmine total dose not to exceed 5 mg) per usual practice</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="74"/>
                <measurement group_id="B2" value="77"/>
                <measurement group_id="B3" value="151"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="56.4" spread="12.8"/>
                <measurement group_id="B2" value="57.0" spread="12.7"/>
                <measurement group_id="B3" value="56.7" spread="12.7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="34"/>
                <measurement group_id="B3" value="61"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="47"/>
                <measurement group_id="B2" value="43"/>
                <measurement group_id="B3" value="90"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Residual Neuromuscular Blockade (NMB) as Defined by a Train-of-Four (TOF) Ratio &lt;0.9 at Post Anesthesia Care Unit (PACU) Entry</title>
        <description>Neuromuscular functioning was monitored by applying four TOF electrical stimulations to the ulnar nerve and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (height) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB, with a higher ratio indicating greater recovery from NMB. A T4/T1 Ratio of &lt;0.9 is indicative of residual NMB.</description>
        <time_frame>At PACU entry on Day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis population consisted of all randomized participants who received at least one dose of study drug (sugammadex or neostigmine/glycopyrrolate) and had a reliable TOF measurement at PACU entry.</population>
        <group_list>
          <group group_id="O1">
            <title>Sugammadex</title>
            <description>Participants receive a single intravenous (IV) bolus dose of sugammadex, 2 or 4 mg/kg, depending on level of neuromuscular recovery</description>
          </group>
          <group group_id="O2">
            <title>Neostigmine/Glycopyrrolate</title>
            <description>Participants receive a single IV bolus dose of neostigmine/glycopyrrolate (neostigmine total dose not to exceed 5 mg) per usual practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="74"/>
                  <measurement group_id="O2" value="76"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Incidence of Residual Neuromuscular Blockade (NMB) as Defined by a Train-of-Four (TOF) Ratio &lt;0.9 at Post Anesthesia Care Unit (PACU) Entry</title>
            <description>Neuromuscular functioning was monitored by applying four TOF electrical stimulations to the ulnar nerve and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (height) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB, with a higher ratio indicating greater recovery from NMB. A T4/T1 Ratio of &lt;0.9 is indicative of residual NMB.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sugammadex is the numerator and Neostigmine/Glycopyrrolate is the denominator.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>Pearson's Chi-square test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.000</ci_lower_limit>
            <ci_upper_limit>0.059</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Start of Study Drug Administration to Operating Room Discharge-ready</title>
        <description>The time of operating room discharge readiness was determined by the surgical team based on clinical evaluations.</description>
        <time_frame>Day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis population consisted of all randomized participants who received at least one dose of study drug (sugammadex or neostigmine/glycopyrrolate).</population>
        <group_list>
          <group group_id="O1">
            <title>Sugammadex</title>
            <description>Participants receive a single intravenous (IV) bolus dose of sugammadex, 2 or 4 mg/kg, depending on level of neuromuscular recovery</description>
          </group>
          <group group_id="O2">
            <title>Neostigmine/Glycopyrrolate</title>
            <description>Participants receive a single IV bolus dose of neostigmine/glycopyrrolate (neostigmine total dose not to exceed 5 mg) per usual practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="74"/>
                  <measurement group_id="O2" value="77"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time From Start of Study Drug Administration to Operating Room Discharge-ready</title>
            <description>The time of operating room discharge readiness was determined by the surgical team based on clinical evaluations.</description>
            <units>minutes</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15.02" lower_limit="13.23" upper_limit="17.05"/>
                  <measurement group_id="O2" value="18.05" lower_limit="15.94" upper_limit="20.43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sugammadex is the numerator and neostigmine/glycopyrrolate is the denominator. Used log-transformed time intervals.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.021</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for age, American Society of Anesthesiologists class, Body Mass Index, comorbidity index &amp; length of surgical procedure</method_desc>
            <param_type>Estimated Ratio of Geometric Means</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 7 days after administration of study drug</time_frame>
      <desc>Treatment emergent adverse events in the All Patients as Treated population which consisted of all randomized participants who received at least one dose of study drug (sugammadex or neostigmine/glycopyrrolate).</desc>
      <group_list>
        <group group_id="E1">
          <title>Sugammadex</title>
          <description>Participants receive a single intravenous (IV) bolus dose of sugammadex, 2 or 4 mg/kg, depending on level of neuromuscular recovery</description>
        </group>
        <group group_id="E2">
          <title>Neostigmine/Glycopyrrolate</title>
          <description>Participants receive a single IV bolus dose of neostigmine/glycopyrrolate (neostigmine total dose not to exceed 5 mg) per usual practice</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Gastronintestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Delayed recovery from anaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Post procedural myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="74"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agrees to provide to the Sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication and slides and texts of oral or other presentations that report any results of the trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Late Stage Development Group Leader</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
